Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
Nate Edwards of Arya Consulting, Elisabeth Gardiner of Tevard Biosciences, and Donny Xu of the RTW Institute discuss global competition for rare disease therapies.
This week addressed AI accountability, CPHI award winners, NFC anticounterfeiting, first-in-class FDA approvals, and a shelved FDA voucher pilot lead this week’s roundup.
Cole and Jaenisch explain why defending against AI poisoning in pharma manufacturing calls for a data steward role, immutable instruction ledgers, and automation.
The FDA’s new CBER Safety Council separates post-market biologics safety review from approvals, raising oversight for cell and gene therapy developers.